Network Pharmacology Was Applied to Explore the Mechanism of Remimazolam Applied in General Anesthesia for Gynecological Surgeries

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-64
SponsorSecond Hospital of Shanxi Medical University

About this trial

To explore the related mechanisms by which remimazolam regulates hemodynamic stability, inflammatory factors and the immune system in patients undergoing general anesthesia for gynecological surgeries.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The patient or their family members sign the informed consent form

Age: 18-64 years old, BMI: 18-30kg/m2

ASA Grade Ⅰ or Ⅱ

Patients undergoing gynecological surgeries (laparoscopic total hysterectomy, adnexectomy and myomectomy)

Disqualifiers

People who are allergic to remimazolam or benzodiazepinesThyroid disease

Long-term use of benzodiazepines

Pregnancy or lactation

Have a history of drug abuse or alcoholism

Trial design

Design model

Parallel

Treatments tested in this trial

  • Remimazolam

    Drug

    Remimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance

  • propofol

    Drug

    Propofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Remimazolam groupExperimental treatment 1 intervention
Group B: Propofol groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Levels of serum N/OFQ, IL-6, STAT3

Time frame
perioperatively/periprocedurally

Secondary outcomes

1

Heart rate

Time frame
during the surgery
2

mean arterial pressure

Time frame
during the surgery

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: